63 related articles for article (PubMed ID: 16705943)
21. Prognostic role of p53 messenger ribonucleic acid expression in patients after curative resection for stage I to III colorectal cancer: association with colon cancer stem cell markers.
Huh JW; Kim HR; Kim YJ
J Am Coll Surg; 2013 Jun; 216(6):1063-9. PubMed ID: 23571142
[TBL] [Abstract][Full Text] [Related]
22. Biomolecular markers as determinants of patients selection for adjuvant chemotherapy of sporadic colorectal cancers.
Sudoyo AW
Acta Med Indones; 2010 Jan; 42(1):45-50. PubMed ID: 20737746
[TBL] [Abstract][Full Text] [Related]
23. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection.
Molleví DG; Serrano T; Ginestà MM; Valls J; Torras J; Navarro M; Ramos E; Germà JR; Jaurrieta E; Moreno V; Figueras J; Capellà G; Villanueva A
Carcinogenesis; 2007 Jun; 28(6):1241-6. PubMed ID: 17259658
[TBL] [Abstract][Full Text] [Related]
24. Detection of mutated K12-ras in histologically negative lymph nodes as an indicator of poor prognosis in stage II colorectal cancer.
Belly RT; Rosenblatt JD; Steinmann M; Toner J; Sun J; Shehadi J; Peacock JL; Raubertas RF; Jani N; Ryan CK
Clin Colorectal Cancer; 2001 Aug; 1(2):110-6. PubMed ID: 12445369
[TBL] [Abstract][Full Text] [Related]
25. SMAD4 as a prognostic marker in colorectal cancer.
Alazzouzi H; Alhopuro P; Salovaara R; Sammalkorpi H; Järvinen H; Mecklin JP; Hemminki A; Schwartz S; Aaltonen LA; Arango D
Clin Cancer Res; 2005 Apr; 11(7):2606-11. PubMed ID: 15814640
[TBL] [Abstract][Full Text] [Related]
26. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
Tang R; Wang JY; Fan CW; Tsao KC; Chen HH; Wu CM; Chen JS; Changchien CR; Hsieh LL
Cancer Lett; 2004 Jul; 210(1):101-9. PubMed ID: 15172127
[TBL] [Abstract][Full Text] [Related]
27. The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival.
Tsamandas AC; Kardamakis D; Ravazoula P; Zolota V; Salakou S; Tepetes K; Kalogeropoulou C; Tsota I; Kourelis T; Makatsoris T; Karavias D; Scopa CD; Bonikos DS; Kalofonos HP; Petsas T
Strahlenther Onkol; 2004 Apr; 180(4):201-8. PubMed ID: 15057430
[TBL] [Abstract][Full Text] [Related]
28. The DCC protein and prognosis in colorectal cancer.
Shibata D; Reale MA; Lavin P; Silverman M; Fearon ER; Steele G; Jessup JM; Loda M; Summerhayes IC
N Engl J Med; 1996 Dec; 335(23):1727-32. PubMed ID: 8929264
[TBL] [Abstract][Full Text] [Related]
29. Chronic inflammatory bowel disease and cancer.
Pohl C; Hombach A; Kruis W
Hepatogastroenterology; 2000; 47(31):57-70. PubMed ID: 10690586
[TBL] [Abstract][Full Text] [Related]
30. [Recent notions on intestinal cancerogenesis, their implications in genetic risk screening and preventive action of non-steroid anti-inflammatory agents].
Couturier D
Bull Acad Natl Med; 2002; 186(2):421-43; discussion 443-5. PubMed ID: 12145848
[TBL] [Abstract][Full Text] [Related]
31. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
32. Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival.
Hotta T; Takifuji K; Arii K; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H
Anticancer Res; 2006; 26(2B):1425-32. PubMed ID: 16619554
[TBL] [Abstract][Full Text] [Related]
33. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W
Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
[TBL] [Abstract][Full Text] [Related]
34. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer.
Arango D; Laiho P; Kokko A; Alhopuro P; Sammalkorpi H; Salovaara R; Nicorici D; Hautaniemi S; Alazzouzi H; Mecklin JP; Järvinen H; Hemminki A; Astola J; Schwartz S; Aaltonen LA
Gastroenterology; 2005 Sep; 129(3):874-84. PubMed ID: 16143127
[TBL] [Abstract][Full Text] [Related]
35. [New prognostic parameters and categories of colorectal carcinoma--correlation with standards].
Micev M; Cosić-Micev M; Krivokapić Z; Marković V; Popović M
Acta Chir Iugosl; 1998; 45(2 Suppl):61-8. PubMed ID: 10951790
[TBL] [Abstract][Full Text] [Related]
36. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis.
Agesen TH; Sveen A; Merok MA; Lind GE; Nesbakken A; Skotheim RI; Lothe RA
Gut; 2012 Nov; 61(11):1560-7. PubMed ID: 22213796
[TBL] [Abstract][Full Text] [Related]
37. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers.
Legendre H; Decaestecker C; Nagy N; Hendlisz A; Schüring MP; Salmon I; Gabius HJ; Pector JC; Kiss R
Mod Pathol; 2003 May; 16(5):491-504. PubMed ID: 12748256
[TBL] [Abstract][Full Text] [Related]
38. Expression Profiles in Stage II Colon Cancer According to APC Gene Status.
Birnbaum DJ; Laibe S; Ferrari A; Lagarde A; Fabre AJ; Monges G; Birnbaum D; Olschwang S;
Transl Oncol; 2012 Apr; 5(2):72-6. PubMed ID: 22496922
[TBL] [Abstract][Full Text] [Related]
39. [Genetic factors and colorectal cancers development: therapeutic impact].
Olschwang S; Viret F; Monges G; Seitz J; Sevenet N; Tiret E; Milano G; Birnbaum D; Bertucci F
Med Sci (Paris); 2006 Jan; 22 Spec No 1():45-9. PubMed ID: 16705943
[TBL] [Abstract][Full Text] [Related]
40. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
